Magenta Therapeutics Stock

MGTA

US55910K1088

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-23 pm EST			5-day change	1st Jan Change
52.33 ^USD	-0.82%		+18.66%	+367.50%

23-09-11	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
23-09-10	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Valuation: Magenta Therapeutics

Capitalization	42.24M 35.93M 33.3M 31.12M 58.01M 3.88B 61.49M 381M 151M 1.83B 158M 155M 6.67B	P/E ratio 2021	-3.42x	P/E ratio 2022	-0.31x
Enterprise value	-39.84M -33.88M -31.4M -29.35M -54.71M -3.66B -57.98M -359M -142M -1.73B -149M -146M -6.29B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	-	Yield 2021 *	-	Yield 2022	-

More valuation ratios * Estimated data

Latest news: Magenta Therapeutics

23-09-11	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
23-09-10	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI
23-08-31	North American Morning Briefing : PCE Inflation -2-	DJ
23-08-24	North American Morning Briefing : Nasdaq Futures -2-	DJ
23-08-17	North American Morning Briefing : Treasury Yields Keep Pushing Higher	DJ
23-08-10	North American Morning Briefing : Attention Turns -2-	DJ
23-08-03	Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index	CI
23-06-23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index	CI
23-05-19	Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer	CI
23-05-15	Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

More news

Analysts' recommendations: Magenta Therapeutics

23-02-28	HC Wainwright Initiates Magenta Therapeutics at Neutral	MT
23-01-26	BTIG Downgrades Magenta Therapeutics to Neutral From Buy	MT
23-01-26	Cowen Downgrades Magenta Therapeutics to Market Perform From Outperform	MT
23-01-26	Wedbush Downgrades Magenta Therapeutics to Neutral From Outperform on MGTA-117 Safety Issues, Lowers Price Targe to $1 From $3	MT
22-12-21	BTIG Lowers Price Target on Magenta Therapeutics to $3 From $6, Maintains Buy Rating	MT

More recommendations

Press Releases: Magenta Therapeutics

23-09-11	Adrenoleukodystrophy Clinical Trials, and Key Companies\|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others	AQ
23-08-07	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
23-05-03	Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus	PR
23-05-03	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
23-05-03	MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders	BU

More press releases

News in other languages: Magenta Therapeutics

21-10-06

Heidelberg Pharma AG: Zwischenmitteilung für die ersten neun Monate 2021

More news

Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.

Employees

Sector

More about the company

Quotes

Date	Price	Change	Volume
26-01-23	52.33 $	-0.82%	989,864
26-01-22	52.76 $	+9.85%	1,445,402
26-01-21	48.03 $	+3.07%	743,115
26-01-20	46.60 $	+5.67%	1,021,737
26-01-16	44.10 $	+0.23%	638,640

Delayed Quote Nasdaq, January 23, 2026 at 04:00 pm EST

More quotes

3 years	5.89	53.79
5 years	5.14	227.2
10 years	5.14	336

	2021	2022
Net sales	-	-
Net income	-71.14M -60.5M -56.08M -52.4M -97.69M -6.54B -104M -641M -254M -3.09B -267M -261M -11.22B	-76.46M -65.03M -60.28M -56.33M -105M -7.03B -111M -689M -273M -3.32B -287M -281M -12.07B
Net Debt	-177M -150M -139M -130M -243M -16.26B -258M -1.59B -633M -7.67B -663M -650M -27.92B	-82.08M -69.81M -64.71M -60.47M -113M -7.54B -119M -739M -294M -3.56B -308M -301M -12.95B

Magenta Therapeutics Stock

Equities

MGTA

US55910K1088

Valuation: Magenta Therapeutics

Chart: Magenta Therapeutics

Latest news: Magenta Therapeutics

Analysts' recommendations: Magenta Therapeutics

Press Releases: Magenta Therapeutics

News in other languages: Magenta Therapeutics

Quotes and Performance

Course Extremes

ETFs: Magenta Therapeutics

Financials

Company Profile

Quotes

1 day	-0.82%
Current month	+367.50%
Current year	+367.50%